Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042963 (
vomiting
)
31,883
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Clinical and laboratory findings from 15 patients with icteric viral hepatitis during pregnancy (VHP) and from 22 patients with intrahepatic cholestasis during pregnancy (CJP) were evaluated statistically in order to find out which parameters might help in order to find out which parameters might help in differentiating the two diseases. Diagnosis was established by needle liver biopsy in all cases. The following data were considered: history, physical examination, erythrocyte sedimentation rate (ESR) serum cholesterol, prothrombin time, total serum bilirubin, SGOT, SGPT, serum alkaline phosphatase, serum protein, serum flocculation tests,
BSP
blood clearance and serum HB Ag.
Vomiting
, high GOT and GPT serum levels, and serum HB Ag positivity suggest VHP diagnosis. Otherwise a severe itching with scratching lesions, high ESR, elevated total cholesterol and serum alkaline phosphatase values mainly if occurring in the later stage of pregnancy are consistent with CJP diagnosis. When clinical and laboratory data from a jaundiced pregnant female do not allow diagnosis, this can be established only on the basis of needle liver biopsy.
...
PMID:The differential diagnosis between intrahepatic cholestatic jaundice and viral hepatitis during pregnancy. 122 May 7
2 types of combined estrogen-progestogen oral contraceptives (OCs) were administered to 40 women for 3 cycles. The women were selected on the basis of willingness to participate and attend the clinic at monthly intervals as well as absences of contraindications to contraceptive steroid therapy. 32 of the women had a family income below Rs. 250/month, 15 had below Rs. 100/month, all at poverty level. Group A was given a combination of Lynestrenol 2.5 mg with Mestranol 0.75 mg (Noracycline 2.5) from day 5 to day 26 of each of 3 cycles. Group B was given Megestrol acetate 4 mg with 0.05 mg ethinyl estradiol from day 5 to day 26 of each of 3 cycles (both groups were equally divided into 20 women each). The women reported for follow-up between 22-25 days of each cycle. Blood samples were collected in 4 consecutive cycles (1st cycle was a control) and analyzed. Side effects such as nausea,
vomiting
, bleeding, and measures of blood pressure and weight were recorded. No significant differences were noted in mean transominases, bilirubin levels, serum proteins, or albuminium/globulin ratio and all were in normal ranges. The women's weights ranged from 26-50 kg and hemoglobin values from 9.6-12 gm. In other tests performed with low dosages of progestogens (0.5-2.5 mg) and estrogens (0.05-0.075 mg) no biochemical evidence of liver dysfunction was found except a slightly higher percentage of raised
BSP
retention in some series. Though gross abnormalities were not observed in commonly used parameters of liver function, it is suggested that previous liver disease with residual damage or history of idiopathic jaundice with pregnancy should be contraindications for use of these drugs. Dosage used should be minimum, compatible with efficacy for both the estrogens and the progestogens.
...
PMID:Metabolic effects of contraceptive steroids IV. Liver function tests--short term observations. 1231 Apr 10